NCT06983795View on ClinicalTrials.gov

Pioneering Advancements in Cardiocerebrovascular Interactions in the Asia pacFIC - Patent Foramen Ovale Study

Not yet recruitingOBSERVATIONAL
Enrollment

1,000

Participants

Timeline

Start Date

July 31, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2030

Conditions
Ischemic StrokePatent Foramen Ovale
Interventions
PROCEDURE

PFO closure using approved PFO closure devices, Surgical PFO closure

PFO closure using approved PFO closure devices, Surgical PFO closure

DRUG

Medical management

"Antiplatelet therapy~* ASA, also called acetylsalicylic acid (Aspirin, Asaphen, Entrophen, Novasen)~* clopidogrel (Plavix)~* ticagrelor (Brilinta)~* dipyridamole (Persantine)~* cilostazol~Anticoagulation therapy~* apixaban (Eliquis)~* dabigatran (Pradaxa)~* edoxaban (Lixiana)~* rivaroxaban (Xarelto)~* warfarin (Coumadin)"

Trial Locations (1)

Unknown

National University Hospital, Singapore

All Listed Sponsors
lead

National University Hospital, Singapore

OTHER

NCT06983795 - Pioneering Advancements in Cardiocerebrovascular Interactions in the Asia pacFIC - Patent Foramen Ovale Study | Biotech Hunter | Biotech Hunter